New drug combinations before and after surgery for stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests new drug combinations given before and after surgery for people with stomach or gastroesophageal cancer that can be removed but is locally advanced (has grown into nearby tissue). The goal is to see if these combinations can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of cancer in the stomach or the area where the stomach meets the esophagus (gastroesophageal junction).
- Your cancer is locally advanced, meaning it has grown into nearby tissue but has not spread to distant organs.
- You have not had any previous treatment (such as surgery, chemotherapy, or radiation) for this cancer.
- You must be in generally good health, able to perform daily activities, and have adequate organ and bone marrow function.
- You cannot have another active cancer, an autoimmune disease, or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.